Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term 0 (Antineoplastic Agents). Found 13 abstracts

Crispen PL, Uzzo RG, Golovine K, Makhov P, Pollack A, Horwitz EM, Greenberg RE, Kolenko VM. Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention. The Prostate. 2007 May;67(6):582-90.
Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global AT. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine. 2007 May 31;356(22):2271-81.
Narra K, Borghaei H, Al-Saleem T, Hoglund M, Smith MR. Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: report of two cases and review of the literature. Leukemia Research. 2006 Jan;30(1):109-14.
Cheng JD, Valianou M, Canutescu AA, Jaffe EK, Lee HO, Wang H, Lai JH, Bachovchin WW, Weiner LM. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Molecular Cancer Therapeutics. 2005 Mar;4(3):351-60.
Held-Warmkessel J. Managing three critical cancer complications. Nursing. 2005 Jan;35(1):58-63; quiz 63-4.
Manne SL, Ostroff JS, Winkel G, Fox K, Grana G, Miller E, Ross S, Frazier T, Buyyounouski MK, Hanlon AL, Eisenberg DF, Horwitz EM, Feigenberg SJ, Uzzo RG, Pollack A, Morrow M, Chen JQ, Yager JD, Russo J, Bassi DE, Fu J, Lopez de Cicco R, Klein-Szanto AJ, Devlin J, Sherman E, Altomare DA, Vaslet CA, Skele KL, De Rienzo A, Devarajan K, Jhanwar SC, McClatchey AI, Kane AB, Testa JR, Murphy ME, Langer CJ, Mehta MP, Viterbo R, Greenberg RE, Al-Saleem T, Canutescu AA, Dunbrack RL, Serebriiskii IG, Fang R, Latypova E, Hopkins R, Vinson C, Joung JK, Golemis EA. Couple-focused group intervention for women with early stage breast cancer. . J Consult Clin Psychol. 2005 Sep 15;73(4):634-46.
Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clinical Colorectal Cancer. 2005 Jul;5(2):108-13.
Tarn C, Godwin AK. Molecular research directions in the management of gastrointestinal stromal tumors. Current treatment options in oncology. 2005 Nov;6(6):473-86.
Damjanov N, Meropol NJ. Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled?. Oncology (Williston Park). 2004 Apr;18(4):479-88; discussion 488, 493.
Langer CJ. Irinotecan in advanced lung cancer: focus on North American trials. Oncology (Huntington). 2004 Jun;18(7 Suppl 4):17-28.
Langer CJ. CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes. Clinical lung cancer. 2004 Dec;6 Suppl 2:S85-8.
Smith ER, Smedberg JL, Rula ME, Xu XX. Regulation of Ras-MAPK pathway mitogenic activity by restricting nuclear entry of activated MAPK in endoderm differentiation of embryonic carcinoma and stem cells. Journal of Cell Biology. 2004 Mar;164(5):689-99.
Sudakin V, Yen TJ. Purification of the mitotic checkpoint complex, an inhibitor of the APC/C from HeLa cells. Methods in Molecular Biology. 2004 Jan;281:199-212.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term 0 (Antineoplastic Agents)

0 (Antineoplastic Agents) Antineoplastic Agents dt [Drug Therapy] tu [Therapeutic Use] Middle Aged Male ai [Antagonists & Inhibitors] Female pd [Pharmacology] pa [Pathology] ae [Adverse Effects] NIH Research Support-Extramural me [Metabolism] Lung Neoplasms aa [Analogs & Derivatives] Non-US Gov't Research Support Protein-Tyrosine Kinase Survival Rate Human ad [Administration & Dosage] co [Complications] Prognosis Molecular Models US Gov't Research Support-PHS Neoplasms EC 2-7-1-112 (Protein-Tyrosine Kinase) Biological Tumor Markers 0 (Taxoids) Aged Protein Kinase Inhibitors Adult mo [Mortality] 0 (Protein Kinase Inhibitors) ch [Chemistry] Biological) 0 (Tumor Markers Antineoplastic Combined Chemotherapy Protocols Non-Small-Cell Lung Carcinoma sc [Secondary] Neoplasm Metastasis Brain Neoplasms Monoclonal Antibodies Monoclonal) 0 (Antibodies Taxoids Tumor Cell Line Comparative Study 31430-18-9 (Nocodazole) Colorectal Neoplasms Retrospective Studies 80 and over Aged Kidney Neoplasms EC 1-17-4 (Ribonucleotide Reductases) 25513-46-6 (Polyglutamic Acid) Epidermal Growth Factor) EC 2-7-1-112 (Receptor Spinal Cord Compression EC 2-7-1 (mTOR protein) Escherichia coli 103882-84-4 (gemcitabine) tu [Therapeutic 1406-18-4 (Vitamin E) Renal Cell Carcinoma Sequence Alignment EC 6-3-2-19 (Ubiquitin-Protein Ligases) Radiosurgery Protein Kinases 0 (Plasmids) Software Pyrimidines 0 (Transcription Factor AP-1) Pure Red-Cell Aplasia 87081-35-4 (leptomycin B) Phenotype 0 (cetuximab) Phytogenic) 0 (Antineoplastic Agents Amino Acid Sequence Homology 17407-37-3 (vitamin E succinate) 0 (Proto-Oncogene Proteins c-fos) 0 (Anticonvulsants) 0 (NF-kappa B) 56-45-1 (Serine) Bone Neoplasms Saccharomyces cerevisiae 0 (polyglutamic acid-paclitaxel) Lymphoma Flow Cytometry metabolism Inhibitors] Complementary DNA Mutation 0 (Quinazolines) 152459-95-5 (imatinib) Small Cell Carcinoma Adrenal Gland Neoplasms Western Blotting made recently to identify and characterize the factors involved in Survival Analysis 0 (Proteins) 33419-42-0 (Etoposide) Transcription Factor AP-1 Camptothecin surgery Vitamin E Multivariate Analysis Cisplatin Fibroblasts Adrenal Cortex Hormones Recombinant Fusion Proteins NF-kappa B Lymphocytic Leukemia-Chronic Polyglutamic Acid Cell Line Clinical Trials Seizures ep [Epidemiology] EC 27137 (Proto-Oncogene Proteins c-raf) Two-Hybrid System Techniques Catalytic Domain Binding Sites User-Computer Interface Serine Endopeptidases Immunohistochemistry Kinetics 0 (MAP Kinase Signaling System) Piperazines Proportional Hazards Models Ubiquitin-Protein Ligases Systems Integration 0 (Nucleic Acid Synthesis Inhibitors) anaphase-promoting complex Incidence 0 (cci 779) ai [Antagonists & 951-77-9 (Deoxycytidine) Cell Adhesion Prostatic Neoplasms Inappropriate ADH Syndrome Palliative Care et [Etiology] called mitotic checkpoint C from HeLa cells therapy DNA-Binding Proteins etiology genetics EC 2-7-1-37 (Protein Kinases) Complementary) 0 (DNA 0 (Neoplasm Proteins) Treatment Outcome 184475-35-2 (gefitinib) and characterization of the APC Amino Acid Sequence Unsaturated) 0 (Fatty Acids
Last updated on Wednesday, February 05, 2020